← back to search

Ina M. Jürgenliemk‐Schulz

Utrecht University · NL
🔎 Find collaborators in Obstetrics and Gynecology · Radiation →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Obstetrics and Gynecology · Radiation
Research interest
Research interests include Endometrial and Cervical Cancer Treatments, Advanced Radiotherapy Techniques, Prostate Cancer Diagnosis and Treatment, and Ovarian cancer diagnosis and treatment.
h-index
56
citations
12,949
works
226
NIH funding
primary concept
Medicine
email

Recent publications

A review on the transition from PDR to HDR brachytherapy (interventional radiotherapy) for treatment of head and neck cancer: Clinical and practical aspects
Brachytherapy 2026cited by 0position: contributordoi
Joint ABS/GEC-ESTRO Consensus Statement on the objectives of training in brachytherapy for physicians
Brachytherapy 2025cited by 3position: contributordoi
Cost-effectiveness of a nurse-led sexual rehabilitation intervention for women treated with radiotherapy for gynaecological cancer in a randomized trial
Radiotherapy and Oncology 2025cited by 0position: contributordoi
Adaptive brachytherapy for cervical cancer in combined 1.5 T MR/HDR suite: Impact of repeated imaging
Technical Innovations & Patient Support in Radiation Oncology 2024cited by 1position: contributordoi
Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas.
2023cited by 24position: contributordoi
Supplementary Figure S3 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Supplementary Figure S1 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Supplementary Figure S5 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Data from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Supplementary Figure S4 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Supplementary Material and Methods S1 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Supplementary Figure S4 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Supplementary Figure S3 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Data from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Supplementary Figure S2 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Supplementary Figure S2 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Supplementary Material and Methods S1 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Supplementary Figure S1 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Supplementary Figure S5 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
2023cited by 0position: contributordoi
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
2022cited by 0position: contributordoi
MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study
The Lancet Oncology 2021cited by 619position: middledoi
Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer
International Journal of Gynecological Pathology 2021cited by 81position: middledoi
ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology
Radiotherapy and Oncology 2021cited by 67position: middledoi
Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis
Radiotherapy and Oncology 2021cited by 59position: middledoi
Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study
International Journal of Radiation Oncology*Biology*Physics 2021cited by 46position: middledoi
Nomogram Predicting Overall Survival in Patients With Locally Advanced Cervical Cancer Treated With Radiochemotherapy Including Image-Guided Brachytherapy: A Retro-EMBRACE Study
International Journal of Radiation Oncology*Biology*Physics 2021cited by 46position: middledoi
Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis.
2021cited by 42position: contributordoi
Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis
Gynecologic Oncology 2021cited by 38position: middledoi
Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future
International Journal of Radiation Oncology*Biology*Physics 2021cited by 34position: middledoi
Online Magnetic Resonance-Guided Radiotherapy (oMRgRT) for Gynecological Cancers
Frontiers in Oncology 2021cited by 27position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Richard Pötter · Advanced Centre for Treatment, Research and Education in Cancer11 papers (2016–2021)Kari Tanderup · Aarhus University Hospital10 papers (2016–2021)Christian Kirisits · Comprehensive Cancer Center Vienna10 papers (2016–2021) · 10 papers (2021–2026)Jacob Christian Lindegaard · Aarhus University Hospital9 papers (2016–2021)Maximilian Schmid · Medical University of Vienna7 papers (2019–2021)Lars Fokdal · Region of Southern Denmark7 papers (2016–2021)Remi A. Nout · Erasmus MC7 papers (2012–2021)Kathrin Kirchheiner · Ludwig Boltzmann Institute for Digital Health and Prevention6 papers (2018–2021)Alina Sturdza · Vienna General Hospital6 papers (2016–2021)Umesh Mahantshetty · Cancer Hospital and Research Institute6 papers (2018–2021)Peter Hoskin · Manchester Academic Health Science Centre6 papers (2016–2021)Barbara Šegedin · University of Ljubljana5 papers (2018–2021)Christine Haie-Méder · Institut Gustave Roussy5 papers (2016–2021)Erik Van Limbergen · Janssen (Belgium)5 papers (2016–2021)Carien L. Creutzberg · Stanford University4 papers (2012–2021)Bas W. Raaymakers · Utrecht University4 papers (2018–2021)Jan J. Jobsen · Utrecht University4 papers (2012–2021)Vincent T.H.B.M. Smit · Erasmus MC4 papers (2012–2021)Tjalling Bosse · Eurofins (Denmark)4 papers (2012–2021)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Obstetrics and Gynecology · Radiation →